Hormonal
Oral ingestion of capsinoids (non-pungent capsaicin analogs) increases whole-body energy expenditure and reduces abdominal fat in humans with metabolically active brown adipose tissue (BAT) through the activation of the TRPV1-SNS-BAT axis.
If you have detectable brown fat, taking capsinoids (6-9 mg daily) may help slightly reduce abdominal fat and increase energy expenditure. However, if you do not have active brown fat, this supplement will likely have no effect on your metabolism. It is safe for long-term use.
our team (111) found that a single oral ingestion of capsinoids increases EE in individuals with metabolically active BAT, but not in those without it... daily ingestion of capsinoids for 6 weeks augments CIT in individuals with low BAT activities... after a 12-week oral ingestion of capsinoids, a slight but significant reduction of abdominal fat was observed in a group of obese individuals
Why this rating
The paper cites multiple human studies (single and chronic ingestion) showing consistent results in BAT-positive individuals, though sample sizes in cited studies vary.
Source
Brown Adipose Tissue, Diet-Induced Thermogenesis, and Thermogenic Food Ingredients: From Mice to Men
Masayuki Saito et al. · Frontiers in Endocrinology · 2020
DOI 10.3389/fendo.2020.00222
More from this paper
- Green tea extract rich in catechins increases energy expenditure and reduces body fat in humans with higher brown adipose tissue (BAT) activities, likely through the activation of TRPV1/TRPA1 channels rather than COMT inhibition.Good
- Brown adipose tissue (BAT) contributes to diet-induced thermogenesis (DIT) in humans, with individuals having higher BAT activity showing significantly higher postprandial energy expenditure compared to those with low BAT activity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →